Phase 3 double-blind trial of monthly oral islatravir vs daily FTC/tenofovir PrEP in 494 cisgender men and transgender women: adverse events 64.3% vs 77.1%, mostly mild; lymphocytes fell 7.4% by month 3 on islatravir, which was stopped early; efficacy not assessed.
RCTn = 494
Landovitz et al. Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study